144 articles in this topic
Discover how a molecule found in Easter Island soil became one of science's most promising tools against aging — and what it means for your health.
The three aging processes that begin as protective responses and become drivers — what can actually be measured in clinic today, and where the human evidence for rapamycin, metformin, NAD precursors and senolytics genuinely stands.
A clinical read of the five upstream hallmarks — genomic instability, telomere attrition, epigenetic drift, loss of proteostasis and disabled autophagy — separating what is measurable in a patient from what is mechanism only, and what has human endpoint data from what does not.
Master the cutting-edge molecular science of TGF-β-driven fibrosis — from epigenetic reprogramming and mechanotransduction to next-generation therapeutic strategies targeting specific pathway nodes in aging tissue.
A sequenced account of the advanced longevity workup — genome, blood, imaging, function, microbiome, proteomics, liquid biopsy — with a stated confidence on every element and a method for turning fifty abnormal values into one first action.
Go beyond the basics and explore the precise molecular machinery that drives TGF-β-mediated fibrosis in aging — from receptor activation to Smad cascades, myofibroblast transformation, and emerging therapeutic targets.
Discover how your body's own repair system can backfire with age, turning helpful healing signals into a slow build-up of scar tissue that stiffens organs and drives aging.
Explore the advanced molecular architecture of purinergic stress signaling — from transcriptional reprogramming and metabolic crosstalk to emerging therapeutic strategies targeting CD38, P2X7, and the ectonucleotidase axis in aging.
Go beneath the surface of cellular alarm signaling — explore the receptor subtypes, enzymatic pathways, and feedback loops that determine whether ATP triggers inflammation or resolution in aging tissue.
Discover how your cells send out tiny chemical SOS messages when under stress — and why this ancient communication system is a key player in how we age.
A clinical guide to what common single-nucleotide variants and curated panels genuinely deliver — pharmacogenomic phenotypes, HLA risk types, polygenic percentiles — and the structural reasons a negative panel in a symptomatic patient tells you almost nothing.
A clinician's guide to interpreting metabolizer phenotype labels, the gene–drug pairs with evidence strong enough to act on today, and why a genotype describes capacity rather than current enzyme activity.
